The objective of this work was to assess the correlation between microvessel density (MVD), pathological stage and disease recurrence in a series of patients who underwent radical prostatectomy for prostate cancer. Pathological material from 75 consecutive radical prostatectomies performed before 1994 without neoadjuvant treatment, in which sufficient follow-up data were available, was reexamined. Paraffin embedded material was re-cut and hematoxylin and eosin (H&E) stained. Areas of maximal angiogenesis within tumor were identified. Expression of CD34 was investigated by using the monoclonal antibody MY 10. Within the areas of maximal angiogenesis, microvessels expressing CD34 were counted and specimens were divided into two groups, one showing a count of less than 90 microvessels per microscopic field at 2006magnification (MVD < 90), the second more than 90 microvessels (MVD > 90). The MVD was then related to pathological stage, Gleason score (GS) and outcome of the disease. Mean followup was 84 months. Clinical or biochemical progression was observed in 38.6% of patients. In low GS cases, MVD was always < 90, whereas in GS 5 -6, half had MVD < 90 and half were > 90. In high GS MVD was always > 90. MVD was positively associated with a higher pathological stage. Progression of the disease was observed in 20% of MVD < 90 and in 51% in MVD > 90 (P ¼ 0.006). MantelHaensz test showed a correlation between MVD and time to progression (P < 0.05). Although problems exist in methods of counting and in the cut-off number of vessels, which can discriminate the risk categories, it may be concluded that microvessel counts, using CD34 monoclonal antibody, can accurately predict the outcome of radical prostatectomy.
Introduction
Microvessel density (MVD) is considered to be a marker of the neo-angiogenetic process, which is responsible for local growth 1 and metastases in tumors. 2 MVD can be assessed on archival pathological slides through the evaluation of immunoreactivity to some endothelial antigens (CD34, 3 CD31, 4 Factor VIII, 5 etc.). CD34, a differentiation stage-specific leukocyte antigen, 6 is an approximately 115 kDa single-chain transmembrane glycoprotein present on the surface of all endothelial cells. 3 The antigen is expressed selectively by human hematopoietic (myeloid and lymphoid) progenitor cells. 7, 8 The function of this protein may be related to cellular adhesion and/or migration because of its structural characteristics and its relative abundance on cellular surface mainly in the region of cell adhesion in the endothelium. A relationship between the amount of microvessels expressing CD34 and metastases has been found in melanoma, 9 in breast cancer, 5 cervical cancer, 10 stomach, 11 lung, 12 and also in prostate cancer (PC) where an increased density of capillaries in comparison with benign prostate tissue was reported. 13 -15 In more recent studies it has also been demonstrated that CD34 quantifies MVD in PC and that it can be useful to identify patients at high-risk of recurrence after radical prostatectomy. 15 The purpose of the present study was to see whether there is a correlation between MVD, assessed by the analysis of CD34 immunoreactivity and disease recurrence (biochemical or clinical) in a series of patients who underwent radical prostatectomy (RP).
Materials and methods
Specimens of 91 RP performed prior to 1994 were reexamined. This date was selected in order to have at least a 5-y follow-up period. Seventy-five were considered suitable for the study (no neo-adjuvant hormonal therapy, paraffin blocks intact, enough material for re-cutting, basal clinical and follow-up data complete). Archival paraffin embedded specimens were re-cut in 3 -5 m thick sections and hematoxylin and eosin stained (H&E). Material was examined with low-power light microscopy to identify the tumoral areas. The tissue-blocks bearing significant amounts of tumor tissue were then re-cut in thin white sections and mounted on silanated slides. These sections were deparaffinized and hydrated. Endogenous peroxidase was inhibited with 3% hydrogen peroxide. The avidin -biotin-peroxidase technique was used for immunohistochemical analysis. CD34 was investigated using the commercially available monoclonal antibody, MY10 (Becton-Dickinson Inc.), in a dilution 1 : 10. The area of maximal CD34 expression was then identified in tumor tissue. Within tumor zones, in the area of maximal angiogenesis, microvessels were counted on a 2006magnification field (0.739 mm 2 ). 16 Any dark staining endothelial cell or cell cluster clearly separate from adjacent structures was considered a single vessel. For practical purposes, tumors were arbitrarily divided into two groups: one with microvessel counts less than or equal to 90 per 2006microscopic field ( Figure 1A ), the second with microvessel counts superior to 90 per 2006microscopic field 15 ( Figure 1B) . This two-level classification of density was made independently by two researchers (MS and NC) without knowledge of the clinical course of the disease.
The statistical analysis was performed by an independent statistician (RN).
Results
The stage distribution of the disease was as follows: pT2a and b ¼ 53 cases; pT3a and b ¼ 15 cases; pT4 ( ¼ bladder neck infiltration) ¼ one case; pN1 ¼ six cases. Positive surgical margins were found in 21 cases (28%). Mean follow-up in this series was 84 months (range 7 -154) and during this period of observation, biochemical or clinical recurrence was observed in 29 out of 75 cases (38.6%).
Microvessel counts (or microvessel density -MVD) were: < 90 in 30 patients, and > 90 in 45 patients. The relationship between MVD and pathological stage was as follows: < 90 in 27/53 stage pT2 (50.9%); in 2/13 stage pT3 (13.3%) and in 1/6 stage pN1 cases (16.6%). MVD > 90 was detected in 26/53 stage pT2 cases (49.1%); in 13/15 stage pT3 (86.6%), in 5/6 stage pN1 cases and in the pT4 case (Table 1) . Table 2 shows the mean vessel counts ( AE standard error) related to the pathological stage.
The relationship between the Gleason score and MVD is shown in Table 3 . Table 4 shows progressions in relation to confined or locally advanced disease stage and MVD. Progression was observed in six out of 30 cases in MVD < 90 group (20%) and in 23 out 45 cases in the MVD > 90 group (51.1%). The chi-square 262 test showed that the difference was significant (w 2 ¼ 7.34, P ¼ 0.006, Yates-corrected w 2 ¼ 6.09, P ¼ 0.013, 95% CI 1.43 -12.17, odds ratio 4.18). The first progression was biochemical (ie prostate specific antigen, PSA) in 2/6 cases with MVD < 90 and in 9/23 cases with MVD > 90 (Yates corrected w 2 ¼ NS). Disease specific mortality was 7/75 (9.3%): one patient belonged to the MVD < 90 group and six to the MVD > 90 group (Yates corrected w 2 ¼ NS). Figure 2 shows the progression free intervals in the two groups. The Mantel-Haensz test analysis demonstrated that the relative risk of progression was 2.55 for the high MVD (P < 0.05). Figure 3 shows microvessel density in progressive and non progressive cases. The scatter plot clearly indicates the distribution of microvessel counts in the two groups. It can be seen that the group without disease progression had more cases with a low microvessel count (< 90) than the group with progressive disease.
Discussion
Our data confirm the existence of a significant correlation between MVD and pathological stage of prostate cancer. This is in agreement with some reports, 17 although in contrast with others. 18 Considering the association of the pathological stage and MVD, low and high MVD were equally distributed in confined disease (50.94% vs 49.06%, Table 1 ) whereas the majority of cases with locally advanced disease showed high MVD. Statistical analysis shows that MVD is positively associated with pathological stage of the disease: confined disease (pT2a-b ¼ 53 cases) has a statistically significant lower MVD in comparison with locally advanced diseases grouped together (pT3a-b, pT4, pN1 ¼ 22 cases) (chi square 262: 9.01, P ¼ 0.002, Yatescorrected chi square 7.52, P ¼ 0.006; 95% CI ¼ 1.73 -24.9, odds ratio ¼ 5.78).
The differences in microvessel counts (Table 2) classified as < 90 and > 90, showed that the two groups were well differentiated: the maximum mean value AE s.e. in MVD < 90 group and the minimum mean value AE s.e. in the > 90 group did not overlap either in pT2 or in ! pT3 tumors. The MVD < 90 and > 90 groups therefore seem to represent two well-defined categories of tumors. The Student's t-test confirmed this finding showing a statistically significant difference.
The evaluation of MVD in relation with the Gleason sum showed, on the whole, that none of the cases with a low Gleason score (2 -4), had a high MVD, whereas for Gleason 5 and 6 about half of the cases had a high MVD (Table 3 ). All cases with a high Gleason score (GS) had high MVD. Thus the relationship between high GS and high MVD 14, 16 is confirmed by our data.
Some authors state that MVD can be predictive in locally advanced disease, but not in organ confined tumors. Examining our progression rates, stratified by pathological stage (confined vs locally advanced disease) and MVD, an overall statistical significance can be detected (P ¼ 0.01, 95% CI 1.43 -12.17). For confined disease the uncorrected w 2 test showed statistically significant less progressions (P ¼ 0.05, 95% CI 0.95 -13.49) whereas with the Yates correction only a trend to minor progression rate in MVD < 90 was found (P ¼ 0.1). Progression rates in locally advanced disease were not statistically different between low and high MVD (P ¼ 0.75; Table 4 ).
The statistical analysis clearly showed a positive correlation between MVD, assessed by CD34 immunostaining, and progression of the disease. Examining the number of progressions (Table 4 ) and time to recurrence (Figure 2) , considering either chemical (PSA) or objective recurrence, the low MVD tumors showed a significantly inferior rate of progression during the follow-up.
Conclusions
From the present data, it may be concluded that MVD (assessed through CD34 immunostaining) in tumoral areas is related to the extension of the disease in clinical T2 tumors. Tumors can be divided in two categories according to the MVD and the count of 90 microvessels can be considered a reliable cut-off value, as proposed by other investigators. Also, the association of high GS with high MVD was confirmed in this study.
On the whole, MVD can accurately predict the outcome of radical prostatectomy in patients with clinically confined disease. Considering the pathological stage, MVD was predictive for recurrence in confined disease, whereas for locally advanced disease, MVD cannot be considered an adjunctive predictor of the outcome.
Nevertheless, some practical problems may presently limit the usefulness of MVD assessment of surgical specimens. In fact, there is no agreement either on methods for counting the microvessels or on the cut-off value, which separates low from high MVD.
Most workers perform MVD assessment according to the method suggested by Weidner et al in 1993, 16 which has also been used in our study. However, unavoidably, each center introduces a number of modifications to the original methods. For instance, it has been suggested that counting the microvessels present in four orthogonally contiguous but not overlapping microscopic fields within the highest microvessel density area (hot spot) 18 increases counting precision. Others propose at least five hot spots, but in almost 20% of cases less than five hot spots can be identified within the neoplastic areas. 15 Finally, other centers, adopt computerized imaging analysis systems to minimize the errors in counting, 13, 17 even though the comparison of 'manual' with computerized counting, in benign and malignant prostate tissue, shows only a 4% discrepancy. 13 The microvessel counts may vary from 14 18 to 300. 14 The number of microvessels significantly associated with progression has been evaluated as greater than 90, 15 127 18 and 160, 14 but the variability of counts within the no progression and progression groups, respectively may be quite high and overlapping counts, as expected, are also frequent also if distant metastases or no metastases groups in patients with invasive disease 16 are considered. Choosing a cut-off value, whatever it is, based on personal mean microvessel counts, below which the prognosis is good, should be considered arbitrary until an accepted validated value is identified.
In spite of these uncertainties, the analysis of MVD with CD34 monoclonal antibody can be considered a reliable adjunctive support for predicting the outcome clinically localized prostate cancer and deserves further extended investigation.
Lastly, in a comparative study, it was demonstrated that MVD measured with CD31 is less significant than CD34 in the prediction of recurrence of disease after radical prostatectomy. 19 
